NEW YORK, Dec. 2, 2016 /PRNewswire/ --Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Fragile X Syndrome in 11 Major Markets
Fragile X syndrome (FXS) is an X-linked dominant genetic disorder. It is caused by a defect in the fragile-X mental retardation 1 gene (FRM1); this defect prevents the FRM1 gene from expressing FMRP. The FMRP protein, most commonly found in the brain, is essential for normal cognitive development and female reproductive function. FXS is the leading genetically inherited cause of intellectual and developmental disability.
This report provides the current prevalent population for Fragile X Syndrome across 11 Major Markets (USA, France, Germany, Italy, Spain, UK, Australia, Japan, Brazil, India and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Fragile-X have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Features associated with Fragile X Syndrome include:
- Autistic-like features
- Fragile X tremor ataxia syndrome (FXTAS)
- Fragile X primary ovarian insufficiency (FXPOI)
- Attention problems- Anxiety
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
- Able to quantify patient populations in the global Fragile X Syndrome market to target the development of future products, pricing strategies and launch plans.
- Gain further insight into the prevalence of the subdivided types of Fragile X Syndrome and identify patient segments with high potential.
- Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
- Provide a level of understanding on the impact from specific co-morbid conditions on Fragile X Syndrome's prevalent population.
- Identify sub-populations within Fragile-x which require treatment.
- Gain an understanding of the specific markets that have the largest number of Fragile-x patients.
Read the full report:
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: firstname.lastname@example.org
Intl: +1 339-368-6001
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/epiomic-epidemiology-series-fragile-x-syndrome-forecast-in-11-major-markets-2016-2026-300372029.html